Omega Diagnostics Group PLC Annual Report and Group Financial Statements 2017 Because health matters PAGE TITLE continued Sub title Operational highlights • Scottish Enterprise grant funding of £1.8 million secured towards planned expansion of Allersys ®  menu • CE mark achieved for 41 allergens to run on IDS-iSYS platform • Four new Allergodip ®  panels now optimised • Recruitment of skilled project managers and leaders into scientific teams • Food intolerance division continues its strong performance • Formal design freeze attained with our VISITECT ®  CD4 test • CE mark achieved for VISITECT ®  Malaria tests to be manufactured at our facility in Pune *  The Group defines adjusted profit before taxation as statutory profit before tax and amortisation of intangible assets, share-based payment charges and  IFRS-related discount charges. We believe that this measure of performance eliminates factors which distort period-on-period comparisons in order to provide a  more comparable position year on year. We believe this information is useful to shareholders and analysts in providing a basis for measuring our financial performance. Sales (£m) £14.2m  12% Gross profit (£m) £9.2m  13% Gross profit (%) 64.7%  0.9% Financial highlights Adjusted profit before tax (£m)* £1.1m  16% 15 16 17 12.1 12.7 14.2 15 16 17 7.7 8.1 9.2 15 16 17 63.4 63.8 64.7 15 16 17 1.4 1.4 1.1 Continuing our progress  with accelerated growth October 2015 Opened manufacturing facility  in Pune, India. August 2016 Secured a Scottish Enterprise  research and development  grant of £1.8 million. November 2016 Accelerated recruitment of  skilled project managers and  leaders into our scientific team. November 2015 Initiated business plan to  accelerate growth across all  three operating segments. October 2016 CE-marked our allergy launch  panel comprising 41 allergens  which are now available for sale. January 2017 Gained ISO accreditation  for manufacturing facility  in Pune, India. OPERATIONAL AND FINANCIAL HIGHLIGHTS For more information on  the new facility in Pune 3  Annual Report and Group Financial Statements 2017 01 Strategic Report March 2017 CE mark achieved for VISITECT ®   range of malaria tests..